Mabpharm Limited (2181) Announces Board Composition and Committee Arrangements

Bulletin Express
2025/10/31

Mabpharm Limited (2181) announced information regarding its Board of Directors and committee memberships as of October 31, 2025. The Board includes both executive and non-executive members, with leadership roles clearly defined. Chairman responsibilities rest with a non-executive member, while the Chief Executive Officer role is held by an executive member.

The company has organized three committees with established terms of reference. The Audit Committee is chaired by an independent non-executive member and includes representatives from non-executive and independent non-executive ranks. The Remuneration Committee is similarly led by an independent non-executive board member, joined by one executive director and another independent non-executive member. The Nomination Committee leadership is undertaken by an independent non-executive member, supported by both executive and independent non-executive directors.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10